MSP-1014 is a serotonergic psychedelic which is under development for the treatment of major depressive disorder, other depressive disorders, and anxiety disorders.Araujo JA, Higgins GA, de Lannoy IA, Dean I, Atkinson J, Lanthier J, Slassi M. (2022 November 13). 147.05 / JJ5 - The preclinical safety, behavioural and pharmacokinetics properties of MSP-1014, a novel prodrug of psilocin. Neuroscience 2022. https://www.abstractsonline.com/pp8/#!/10619/presentation/70912
It is a prodrug of psilocin similarly to psilocybin, and hence acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor. The animal pharmacodynamics and pharmacokinetics of MSP-1014 have been studied, demonstrating a shorter plasma half-life compared to psilocybin.
The drug is under development by Mindset Pharma and Otsuka America Pharmaceutical. As of January 2024, it is in phase 2 clinical trials for major depressive disorder and is in the preclinical stage of development for anxiety disorders and other depressive disorders. The chemical structure of MSP-1014 does not yet seem to have been disclosed. However, Mindset Pharma patented psilocin derivatives and prodrugs in 2022.
See also Substituted tryptamine List of investigational hallucinogens and entactogens CT-4201, EB-002, and RE-109 (4-GO-DMT) Luvesilocin (4-GO-DiPT) MSP-2020
References